1.
Frederiksen BL, Jørgensen T, Brasso K, Holten I, Osler M. Socioeconomic position and
participation in colorectal cancer screening. Br J Cancer. 2010;103(10):1496–501.
2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics
2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
countries. CA Cancer J Clin [Internet]. 2018 Nov 1 [cited 2019 Feb 24];68(6):394–424.
3.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal
Cancer Statistics , 2017. CA Cancer J Clin. 2017;67(3):177–93.
4.
Amin MB, Brookland RK, Compton CC, Gershenwald JE, Edge SB, Winchester DP, et al.
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a
population-based to a more “personalized” approach to cancer staging. CA Cancer J
Clin. 2017;67(2):93–9.
5.
Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular
crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18(3):195–203.
6.
Jang E, Chung DC. Hereditary colon cancer: Lynch syndrome. Gut Liver. 2010;4(2):77–88.
7.
Popat S, Hubner R, Houlston RS. Systematic Review of Microsatellite Instability and
Colorectal Cancer Prognosis. J Clin Oncol [Internet]. 2005;23(3):609–18.
8.
Malesci A, Laghi L, Bianchi P, Montorsi M, Randolph A, Rosati R, et al. Reduced Likelihood
of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer. Clin Cancer
Res. 2007;13(13):3831–9.
9.
NCCN - Colon Cancer. Colon Cancer. NCCN Guidel [Internet]. 2018;1–832. Available from:
www.nccn.org
10.
Laporte GA, Leguisamo NM, Kalil AN, Saffi J. Clinical importance of DNA repair in
sporadic colorectal cancer. Crit Rev Oncol Hematol. 2018;126:168–85.
11.
Mirza-Aghazadeh-Attari M, Darband SG, Kaviani M, Mihanfar A, Aghazadeh Attari J, Yousefi
B, et al. DNA damage response and repair in colorectal cancer: Defects, regulation
and therapeutic implications. DNA Repair (Amst). 2018;69:34–52.
12.
Bodor JN, Handorf EA, Feldman R, Hall MJ. Pathogenic somatic mutation (SM) of mismatch
repair (MMR) genes and associations with microsatellite instability (MSI), tumor mutational
burden (TMB) and SM in other DNA repair pathways in 24,223 tumor genomic profiles.
J Clin Oncol. 2018 May 20;36(15_suppl):1505.
13.
Shibata A, Jeggo PA. DNA Double-strand Break Repair in a Cellular Context. Clin Oncol.
2014;26(5):243–9.
14.
Jekimovs C, Bolderson E, Suraweera A, Adams M, OByrne KJ, Richard DJ. Chemotherapeutic
Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad,
and the Promising. Front Oncol. 2014;4(86):1–18.
15.
Sale JE. Competition, collaboration and coordination - determining how cells bypass
DNA damage. J Cell Sci. 2012;125(7):1633–43.
16.
Zafar MK, Eoff RL. Translesion DNA Synthesis in Cancer: Molecular Mechanisms and Therapeutic
Opportunities. Chem Res Toxicol. 2017;30(11):1942–55.
17.
Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, et al. Polymorphisms
in genes of nucleotide and base excision repair: Risk and prognosis of colorectal
cancer. Clin Cancer Res. 2006;12(7 I):2101–8.
18.
Xu K, Song X, Chen Z, Qin C, He Y, Zhan W. XRCC2 promotes colorectal cancer cell growth,
regulates cell cycle progression, and apoptosis. Medicine (Baltimore). 2014;93(28):e294.
19.
Zhang YZ, An JH, Liu YX, Wu XC, Han SS, Ren XQ, et al. XRCC2-Deficient Cells are Highly
Sensitive to 5-Fluorouracil in Colorectal Cancer. Cell Physiol Biochem. 2017;43(3):1207–19.
20.
Qin C-J, Song X-M, Chen Z-H, Ren X-Q, Xu K-W, Jing H, et al. XRCC2 as a predictive
biomarker for radioresistance in locally advanced rectal cancer patients undergoing
preoperative radiotherapy. Oncotarget. 2015;6(31):32193–204.
21.
Cooper C. AJCC 8 th edition update *: Colorectal cancer Chapter 20.
22.
McDonald JW, Pilgram TK. Nuclear expression of p53, p21 and cyclin D1 is increased
in bronchioloalveolar carcinoma. Histopathology. 1999;34(5):439–46.
23.
Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Joudi Mashhad M, Hassanian SM, et al.
The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis
of clinical trials. J Cell Physiol. 2018;233(1):378–86.
24.
Lee CK, Scott C, Lindeman GJ, Lieschke E, Boyle F, Hamilton A, et al. Phase 1 trial
of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian
cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. Br J
Cancer. 2019;120(3):279–85.
25.
Hoskins PJ, Gotlieb WH. Missed therapeutic and prevention opportunities in women with
BRCA-mutated epithelial ovarian cancer and their families due to low referral rates
for genetic counseling and BRCA testing: A review of the literature. CA Cancer J Clin.
2017;67(6):493–506.
26.
Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations
on breast cancer prognosis. Medicine (Baltimore). 2016;95(40):e4975.
27.
Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, et al. Prognostic and
predictive roles of high-degree microsatellite instability in colon cancer: A National
Cancer Institute-national surgical adjuvant breast and bowel project collaborative
study. J Clin Oncol. 2007;25(7):767–72.
28.
Markowitz SD, Bertagnolli MM. Molecular Basis of Colorectal Cancer. N Engl J Med.
2009;361:2449–60.
29.
Kim MJ, Jeong S-Y, Choi S, Ryoo S-B, Park JW, Park KJ, et al. Survival Paradox Between
Stage IIB/C (T4N0) and Stage IIIA (T1-2N1) Colon Cancer. Ann Surg Oncol. 2015;22(2):505–12.
30.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade
in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.
31.
Le D, Durham J, Smith K, Wang H, Bartlett B, Aulakh L, et al. Mismatch repair deficiency
predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.
32.
Halvarsson B, Anderson H, Domanska K, Lindmark G, Nilbert M. Clinicopathologic Factors
Identify Sporadic Mismatch Repair–Defective Colon Cancers. Am J Clin Pathol. 2008;129(2):238–44.
33.
Yang Y, Wang D, Jin L, Wu G, Bai Z, Wang J, et al. Prognostic value of the combination
of microsatellite instability and BRAF mutation in colorectal cancer. Cancer Manag
Res. 2018;10:3911–29.
34.
Bostian A, Maddukuri L, Reed M, Savenka T, Hartman J, Davis L, et al. Kynurenine signaling
increases DNA polymerase kappa expression and promotes genomic instability in glioblastoma
cells. Chem Res Toxicol. 2016;29(1):101–8.
35.
Peng C, Chen D, Wang H-W, Wang S, Qiu W, You Y, et al. The Error-Prone DNA Polymerase
κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation
of ATR-Chk1 Signaling. Cancer Res. 2016;76(8):2340–53.
36.
Zhou W, Chen YW, Liu X, Chu P, Loria S, Wang Y, et al. Expression of DNA translesion
synthesis polymerase η in head and neck squamous cell cancer predicts resistance to
gemcitabine and cisplatin-based chemotherapy. PLoS One. 2013;8(12):1–10.
37.
Teng KY, Qiu MZ, Li ZH, Luo HY, Zeng ZL, Luo RZ, et al. DNA polymeraseη protein expression
predicts treatment response and survival of metastatic gastric adenocarcinoma patients
treated with oxaliplatin-based chemotherapy. J Transl Med. 2010;8:1–9.
38.
Ceppi P, Novello S, Cambieri A, Longo M, Monica V, Lo Iacono M, et al. Polymerase
η mRNA expression predicts survival of non-small cell lung cancer patients treated
with platinum-based chemotherapy. Clin Cancer Res. 2009;15(3):1039–45.
39.
Lemée F, Bavoux C, Pillaire MJ, Bieth A, Machado CR, Pena SD, et al. Characterization
of promoter regulatory elements involved in downexpression of the DNA polymerase κ
in colorectal cancer. Oncogene. 2007;26(23):3387–94.
40.
Pillaire MJ, Bétous R, Hoffmann JS. Role of DNA polymerase κ in the maintenance of
genomic stability. Mol Cell Oncol. 2014;1(1).
41.
Wang Y, Seimiya M, Kawamura K, Yu L, Ogi T, Nakagawara A, et al. Elevated expression
of DNA polymerase κ in human lung cancer is associated with p53 inactivation: Negative
regulation of POLK promoter activity by p53. Int J Oncol. 2004;25(17):161–5.
42.
O-Wang J, Kawamura K, Tada Y, Ohmori H, Kimura H, Sakiyama S, et al. DNA polymerase
κ, implicated in spontaneous and DNA damage-induced mutagenesis, is overexpressed
in lung cancer. Cancer Res. 2001;61(14):5366–9.
43.
Wood RD, Doublie S. DNA polymerase θ (POLQ), double-strand break repair, and cancer.
DNA Repair (Amst). 2016;44:22–32.
44.
Kawamura K, Bahar R, Seimiya M, Chiyo M, Wada A, Okada S, et al. DNA polymerase is
preferentially expressed in lymphoid tissues and upregulated in human cancers. Int
J Cancer. 2004;109(1):9–16.
45.
Pillaire M-J, Selves J, Gordien K, Gouraud P-A, Gentil C, Danjoux M, et al. A ‘DNA
replication’ signature of progression and negative outcome in colorectal cancer. Oncogene.
2010;29(6):876–87.
46.
Lemee F, Bergoglio V, Fernandez-Vidal A, Lacroix-Triki M, Pillaire M-J, Grimal F,
et al. DNA polymerase up-regulation is associated with poor survival in breast cancer,
perturbs DNA replication, and promotes genetic instability. Proc Natl Acad Sci. 2010;107(30):13390–5.
47.
Allera-Moreau C, Rouquette I, Lepage B, Walschaerts M, Gordien K, Hoffmann JS, et
al. DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN
upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients.
Oncogenesis. 2012;1(e30):1–10.
48.
Pucci S, Polidoro C, Joubert A, Mastrangeli F, Tolu B, Benassi M, et al. Ku70, Ku80,
and sClusterin: A Cluster of Predicting Factors for Response to Neoadjuvant Chemoradiation
Therapy in Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys.
2017;97(2):381–8.
49.
Wang S, Wang M, Yin S, Fu G, Li C, Chen R, et al. A novel variable number of tandem
repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5
is a risk factor for human bladder cancer. Mutat Res - Fundam Mol Mech Mutagen. 2008;638(1–2):26–36.
50.
Xiao X, Xiao Y, Cheng W, Wang J, Liu Q, Wu T, et al. Ku80 cooperates with CBP to promote
COX-2 expression and tumor growth. Oncotarget. 2015;6(10):8046–61.
51.
Komuro Y, Watanabe T, Hosoi Y, Matsumoto Y, Nakagawa K, Tsuno N, et al. The expression
pattern of Ku correlates with tumor radiosensitivity and disease free survival in
patients with rectal carcinoma. Cancer. 2002;95(6):1199–205.
52.
Han L, Wu Z, Zhao Q. Revealing the molecular mechanism of colorectal cancer by establishing
LGALS3-related protein-protein interaction network and identifying signaling pathways.
Int J Mol Med. 2014;33(3):581–8.
53.
Lu Y, Gao J, Lu Y. Down-expression pattern of Ku70 and p53 coexisted in colorectal
cancer. Med Oncol. 2015;32(4):98.
54.
Buzon B, Grainger R, Huang S, Rzadki C, Junop MS. Structure-specific endonuclease
activity of SNM1A enables processing of a DNA interstrand crosslink. Nucleic Acids
Res. 2018;46(17):9057–66.